Profile: Perrigo Company PLC (PRGO.K)

PRGO.K on New York Consolidated

24 Apr 2015
Change (% chg)

$-8.74 (-4.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Perrigo Company plc, incorporated on March 23, 1988, is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. The Company’s businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia, and distributes into dozens of other markets worldwide, including Canada, China and Latin America. In February 2014, the Company announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc.

The Company operates through several wholly owned subsidiaries. In the United States, its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., PBM Products, LLC, PBM Nutritionals, LLC, Paddock Laboratories, LLC, Perrigo Diabetes Care, LLC (formerly CanAm Care, LLC), Sergeant's Pet Care Products, Inc. and Fidopharm, Inc. Outside the United States, its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Galpharm Healthcare Ltd., Orion Laboratories Pty Ltd and Rosemont Pharmaceuticals Ltd.

Consumer Healthcare

Perrigo Consumer Healthcare (CHC) operation includes the Company's United States, United Kingdom and Mexico manufacturing operations supporting the sale of OTC pharmaceutical products. Perrigo CHC supplies more than 15 categories and 500 formulas and offers analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as well as vitamins, dietary supplements and nutritional drinks. Perrigo offers a range of products, such advertised brand products as Tylenol, Advil or One-A-Day. Tylenol has acetaminophen as an active ingredient and is available in stores' analgesic (pain reliever) aisle. Store-brand acetaminophen is located next to the national brand, offering the same active ingredient (acetaminophen) and the same pain relief.

Perrigo Nutritionals

Perrigo is a manufacturer of nutrition products for the store brand market. Nutrition products include infant formula, pediatric nutritionals and vitamins, minerals, and supplements. Acquired by Perrigo, Perrigo Nutritionals, formerly PBM Products, LLC, had introduced private-label, or store-brand infant formulas to the United States. Perrigo Nutritionals is the supplier of store-brand infant formulas and nutrition products. With distribution to major retailers, Perrigo Nutritional products can be found in more than 40,000 retail locations around the world. Its pediatric nutritionals business extends its offerings to children well beyond infancy. Its baby cereals, toddler foods, and pediatric nutritional drinks are available as store brands at various retail locations throughout the United States and the international community. Perrigo manufactures a range of vitamins, minerals, and supplements, in every major segment of the business. Marketed under the store brand labels of the retailers in the food, drug, mass-merchandise and wholesale club channels, it manufactures over 395 formulas of dietary supplements. Its brands include Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex.

Rx Pharmaceuticals

The Company’s Rx Pharmaceuticals business is focused on the development, manufacture and sale of generic prescription drug products, primarily for the United States market. Manufacturing operations are based in the United States and Israel. Perrigo's portfolio focuses on complex, high-barrier ophthalmological, topical foam and oral liquid formulations. Its products include Acetylcysteine Injection 200 mg/mL (6g/30mL), Acetylcysteine Injection 6 g/30 mL (200 mg/1 mL), NOVAPLUS, ACTIDOSE with SORBITOL, ACTIDOSE-AQUA, ASPIRIN SUPPOSITORIES USP, Bacitracin Ophthalmic Ointment USP, Belladonna and Opium Suppositories C-II, BENZOIN COMPOUND TINCTURE USP, Benzoyl Peroxide 10% Acne Medication Wash, CLOBETASOL PROPIONATE LOTION 0.05% and Docusate Sodium.

Active Pharmaceutical Ingredients

Primarily through the Company’s Israel-based business, Perrigo develops, manufactures and markets the complex chemicals and active pharmaceutical ingredients used worldwide by the generic drug industry. Certain of these ingredients are also used in Perrigo's own pharmaceutical products. It manufactures API at facilities in Israel, India and China. Perrigo API specializes in tailor-made research and process development of APIs and Finished Dosage Forms (FDFs).

Life Sciences

Through the Company’s Israel-based business, Perrigo markets and manufactures branded prescription drugs and medical diagnostic products through exclusive agreements with pharmaceutical companies. Its Pharmaceutical and Medical Diagnostic Products businesses also market and manufacture branded prescription drugs under licenses. Other pharmaceutical and medical diagnostics products are imported to Israel through exclusive agreements. Products in life sciences segment include TYSABRI and ELND005. TYSABRI (natalizumab) is indicated for treatment of: Multiple Sclerosis: as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. TYSABRI is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy; Crohn’s Disease (CD): Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor-α.


Perrigo's Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses. Other pharmaceutical and medical diagnostic products are imported to Israel through exclusive agreements with pharmaceutical and diagnostics companies. This business is divided into two departments: Pharma-Israel and Tayco Diagnostics. Pharma-Israel operates in the Israeli market as a partner in the marketing, sales and distribution of Rx (dermatology, gastroenterology, blood products, CNS, urology and other fields), OTC, generics, branded generics, dermo-cosmetics and dietary supplements. Tayco, the diagnostics division of Perrigo-Israel Pharmaceuticals Ltd., specializes in marketing and sales of medical laboratory systems, reagents, accessories and consumables. It also markets self-monitoring medical devices for diagnosis and treatment of diabetes. The division operates throughout Israel to service the central laboratory, hospital, clinic, point of care and self-testing markets. Its activities in the medical and research fields in Israel cover all market segments: medical (private and public health services), research institutions and the biotech industry.

The Company competes with Dr. Reddy’s Laboratories, Ltd., Actavis Inc., Aaron Industries, Inc., Ohm Laboratories, Inc., PL Developments, LNK International, Inc., Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber), Danone Baby Nutrition, Bayer AG, Pfizer, Inc., Rexall Sundown, Inc., Apotex, Glenmark Generics Inc., Impax, Prasco, Sandoz, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, and Zydus Pharmaceuticals.

Company Address

Perrigo Company PLC

Treasury Building
Lower Grand Canal Street, Dublin

Company Web Links

Search Stocks